Trevi Historical Cash Flow
| TRVI Stock | USD 4.26 0.05 1.19% |
Analysis of Trevi Therapeutics cash flow over time is an excellent tool to project Trevi Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 148.5 K or Dividends Paid of 2.7 M as it is a great indicator of Trevi Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Trevi Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Trevi Therapeutics is a good buy for the upcoming year.
Trevi |
About Trevi Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Trevi balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Trevi's non-liquid assets can be easily converted into cash.
Trevi Therapeutics Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Trevi Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Trevi Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Trevi Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Trevi Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trevi Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.As of now, Trevi Therapeutics' Depreciation is increasing as compared to previous years. The Trevi Therapeutics' current Change To Account Receivables is estimated to increase to about 353.8 K, while Change To Inventory is forecasted to increase to (250.5 K).
Trevi Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Trevi Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Trevi Therapeutics cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Sale Purchase Of Stock | 10.5M | (1.2M) | (331K) | 117.2M | 134.7M | 141.5M | |
| Investments | (32K) | (107.2M) | (126.2M) | (1.7M) | (1.6M) | (1.6M) | |
| Change In Cash | (12.3M) | (8.2M) | (24.2M) | 19.8M | 17.8M | 18.7M | |
| Stock Based Compensation | 2.4M | 2.5M | 2.3M | 2.2M | 2.6M | 1.6M | |
| Free Cash Flow | (29.0M) | (28.9M) | (28.3M) | (31.8M) | (28.7M) | (30.1M) | |
| Change In Working Capital | 1.1M | 1.5M | (1.2M) | (3.8M) | (3.5M) | (3.3M) | |
| Begin Period Cash Flow | 57.3M | 45.0M | 36.8M | 12.6M | 14.5M | 27.5M | |
| Total Cashflows From Investing Activities | (158K) | (9K) | (32K) | (107.4M) | (96.6M) | (91.8M) | |
| Other Cashflows From Financing Activities | (415K) | (408K) | 11.7M | (211K) | (189.9K) | (180.4K) | |
| Depreciation | 47K | 50K | 43K | 123K | 141.5K | 148.5K | |
| Other Non Cash Items | 227K | 974K | (162K) | (1.2M) | (1.1M) | (998.6K) | |
| Capital Expenditures | 9K | 32K | 159K | 137K | 157.6K | 93.5K | |
| Total Cash From Operating Activities | (29M) | (28.9M) | (28.2M) | (31.7M) | (28.5M) | (30.0M) | |
| Change To Operating Activities | 1.2M | 348K | 678K | (1.2M) | (1.1M) | (1.1M) | |
| Net Income | (32.8M) | (33.9M) | (29.2M) | (29.1M) | (26.2M) | (27.5M) | |
| Total Cash From Financing Activities | 16.7M | 20.8M | 111.3M | (7.9M) | (9.1M) | (8.6M) | |
| End Period Cash Flow | 45.0M | 36.8M | 12.6M | 32.4M | 37.3M | 30.5M | |
| Change To Netincome | 1.3M | 2.4M | 2.8M | 2.3M | 2.7M | 2.2M | |
| Change To Liabilities | 777K | 417K | 831K | (630K) | (724.5K) | (688.3K) | |
| Issuance Of Capital Stock | 3.1M | 21.2M | 105.4M | 4.1M | 4.7M | 4.5M |
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trevi Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trevi Therapeutics. If investors know Trevi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trevi Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Trevi Therapeutics is measured differently than its book value, which is the value of Trevi that is recorded on the company's balance sheet. Investors also form their own opinion of Trevi Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Trevi Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trevi Therapeutics' market value can be influenced by many factors that don't directly affect Trevi Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trevi Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Trevi Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trevi Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.